方盛制药控股子公司获得《药品生产许可证》

Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) has received a Drug Production License from the Guangdong Provincial Drug Administration for its subsidiary, Guangdong Fangsheng Ronghua Pharmaceutical Co., Ltd., allowing it to hold the marketing authorization for RuLuGuoLi tablets [1] Group 1 - The Drug Production License enables the company and its subsidiary to integrate and allocate production and sales resources [1] - This development is expected to improve capacity utilization and reduce production costs [1] - The immediate impact on the company's financial performance is not expected to be significant [1]

Fangsheng Pharmaceutical-方盛制药控股子公司获得《药品生产许可证》 - Reportify